動(dòng)物腫塊測(cè)量?jī)x，非常適合對(duì)大鼠小鼠等動(dòng)物的皮下**進(jìn)行快速測(cè)量、分析，精確測(cè)量動(dòng)物腫塊并對(duì)腫塊信息存檔與跟蹤。

主要技術(shù)參數(shù)： 

· 測(cè)量范圍：0-25mm**尺寸：20*20*20mm
· 3D測(cè)量精確度：<0.3mm
· 圖像捕捉時(shí)間：0.1s
· 接口：USB 2.0
· 相機(jī)：1600*1200 像素（2MP）
· 工作距離：50mm

動(dòng)物**測(cè)量分析儀的主要特點(diǎn)： 
· 手持式成像裝置，實(shí)現(xiàn)立體成像；
· 適合測(cè)量不同尺寸的腫塊；
· 方便使用：觸屏式電腦，操作方便；
· 內(nèi)置軟件，自動(dòng)計(jì)算**尺寸，跟蹤整個(gè)實(shí)驗(yàn)進(jìn)展。 
  

· 快速，高效，保證了高通量和可靠測(cè)量；
· 全自動(dòng)測(cè)量跟蹤系統(tǒng)；
· 實(shí)時(shí)數(shù)據(jù)分析與處理。 

部分用戶： 

Hunter College, CUNY

Vanderbilt University Medical Center

Hainan Medical University

Howard Hughes Medical Institute

Memorial Sloan Kettering Cancer Center

Cancer Center Amsterdam

GlaxoSmithKline

Imec

K.U.Leuven

Neuro-Electronics Research Flanders

Pepric

PharmaVize

reMYND

University Ghent

SEPS Pharma

Vlaams Instituut voor Biotechnologie

University Antwerp

ThromboGenics

Janssen Pharmaceutica

City University of Hong Kong

參考文獻(xiàn)：

1.Adams EJ, Karthaus WR, Hoover E, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408-412. doi:10.1038/s41586-019-1318-9.
2.Zhang Z, Zhou C, Li X, et al. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell. 2020;37(4):584-598.e11. doi:10.1016/j.ccell.2020.03.001.
3.Santich BH, Park JA, Tran H, et al. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Sci Transl Med. 2020;12(534):eaax1315. doi:10.1126/scitranslmed.aax1315.
4.Park JA, Xu H, Cheung, I, et al. Abstract B38: Tetravalent bispecific antibodies specific for HER2 and disialoganglioside GD2 to engage polyclonal T cells for osteosarcoma therapy. Cancer Res. 2018;78(19),B38.doi:10.1158/1538-7445.PEDCA17-B38.
5.Wu CF, Wu CY, Lin CF, et al. The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice. Biomed Pharmacother. 2022;151:113128. doi:10.1016/j.biopha.2022.113128.
6.Wang L, Hoseini SS, Xu H, et al. Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency. Cancer Immunol Res. 2019;7(12):2013-2024. doi:10.1158/2326-6066.CIR-19-0121.
7.Grochowska A, Statkiewicz M, Kulecka M, et al. Evidence supporting the oncogenic role of BAZ1B in colorectal cancer. Am J Cancer Res. 2022;12(10):4751-4763. 
8.Hoseini SS, Vadlamudi M, Espinosa-Cotton M, et al. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. J Immunother Cancer. 2021;9(5):e002509. doi:10.1136/jitc-2021-002509.
9.Beguin E, Gray MD, Logan KA, et al. Magnetic microbubble mediated chemo-sonodynamic therapy using a combined magnetic-acoustic device. J Control Release. 2020;317:23-33. doi:10.1016/j.jconrel.2019.11.013.
10.Mao N, Gao D, Hu W, et al. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes. Mol Cancer Ther. 2019;18(9):1577-1586. doi:10.1158/1535-7163.MCT-18-1386.
11.Wu Z, Guo HF, Xu H, et al. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers. Mol Cancer Ther. 2018;17(10):2164-2175. doi:10.1158/1535-7163.MCT-18-0026.
12.Poty S, Mandleywala K, O'Neill E, et al. 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics. 2020;10(13):5802-5814. doi:10.7150/thno.44772.
13.Hoseini SS, Guo H, Wu Z, et al. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Adv. 2018;2(11):1250-1258. doi:10.1182/bloodadvances.2017014373.
14.Zhang Z, Karthaus WR, Lee YS, et al. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. 2020;38(2):279-296.e9. doi:10.1016/j.ccell.2020.06.005.
15.Poty S, Carter LM, Mandleywala K, et al. Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2019;25(2):868-880. doi:10.1158/1078-0432.CCR-18-1650.